As one of the most popular therapeutic studies ,immunotherapy has proved effective in many systemic tumor clinical trials.Programmed death ligand 1(PD-L1) is a molecule involved in immunosuppression pathway ,significantly expressed on the surface of plenty of solid tumor cells and the peripheral T lymphocytes , which can combine with pro-grammed death receptor 1(PD-1),inhibit the immune microenvironment around tumor tissue ,and promote the deterioration of the tumor cells.PD-1/PD-L1 expression is not only associated with the prognosis of patients and clinical staging ,but is also expected to become an independent clinical biomarker ,and provides new target for tumor immunotherapy .%免疫治疗作为当前最热门的治疗研究领域之一,在诸多系统肿瘤临床试验中证实疗效显著.程序性死亡配体1(PD-L1)是一种参与免疫抑制通路的分子,在较多实体肿瘤细胞及其周围T淋巴细胞表面显著表达,能与其受体程序性死亡受体1(PD-1)结合,抑制肿瘤组织周围的免疫微环境,促进肿瘤细胞的恶化.PD-1/PD-L1的表达不仅与患者的预后及临床分期具有一定的相关性,同时还有望成为独立的临床生物标志物,进而为肿瘤的免疫治疗提供新的靶点.
展开▼
